Cempra Inc(NASDAQ:CEMP) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Company reported revenue of $3.42M. Analysts estimated a revenue of $3.89M. Earnings per share were $-0.51. Analysts had estimated an EPS of $-0.67.
In a different note, JP Morgan said it Initiates Coverage on Cempra Inc, according to a research note issued on Jul 12, 2016. The shares have been rated ‘Overweight’ by the firm. On Jun 7, 2016, Roth Capital said it Reinstates its rating on Cempra Inc. The shares have been rated ‘Buy’ by the firm.
Cempra Inc (CEMP) shares turned negative on Mondays trading session with the shares closing down -0.17 points or -0.70% at a volume of 14,57,684. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $25.09. The peak price level was also seen at $25.09 while the days lowest was $23.31. Finally the shares closed at $23.97. The 52-week high of the shares is $41.4299 while the 52-week low is $14.03. According to the latest information available, the market cap of the company is $1,246 M.
Several Insider Transactions has been reported to the SEC. On Mar 2, 2016, David Moore (Chief Commercial Officer) purchased 500 shares at $16.18 per share price.Also, On Jan 6, 2016, Dov A Md Goldstein (director) sold 842 shares at $30.07 per share price.On Dec 15, 2015, David W. Oldach (Chief Medical Officer) sold 10,000 shares at $30.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product solithromycin is being developed in oral capsules intravenous or IV and suspension formulations initially for the treatment of community acquired bacterial pneumonia or CABP an infection of the respiratory tract. The Company’s second product is Taksta an antibiotic known as fusidic acid that has been used for decades outside the United States including Western Europe but which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.